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Autophagy is a dynamic intracellular mechanism involved in protein and organelle
turnover through lysosomal degradation. When properly regulated, autophagy supports
normal cellular and developmental processes, whereas defects in autophagic
degradation have been associated with several pathologies, including prion diseases.
Prion diseases, or transmissible spongiform encephalopathies (TSE), are a group of
fatal neurodegenerative disorders characterized by the accumulation of the pathological
misfolded isoform (PrPSc) of the physiological cellular prion protein (PrPc) in the central
nervous system. Autophagic vacuoles have been described in experimental models of
TSE and in the natural disease in humans. The precise connection of this process with
prion-related neuropathology, or even whether autophagy is completely beneficial or
pathogenic during neurodegeneration, is poorly understood. Thus, the biological role of
autophagy in these diseases is still open to debate. During the last years, researchers
have used a wide range of morphological, genetic and biochemical methods to monitor
and manipulate the autophagic pathway and thus determine the specific role of this
process in TSE. It has been suggested that PrPc could play a crucial role in modulating
the autophagic pathway in neuronal cells, and the presence of abnormal autophagic
activity has been frequently observed in several models of TSE both in vitro and in vivo,
as well as in human prion diseases. Altogether, these findings suggest that autophagy is
implicated in prion neuropathology and points to an impairment or failure of the process,
potentially contributing to the pathogenesis of the disease. Additionally, autophagy is
now emerging as a host defense response in controlling prion infection that plays a
protective role by facilitating the clearance of aggregation-prone proteins accumulated
within neurons. Since autophagy is one of the pathways of PrPSc degradation, and drug-
induced stimulation of autophagic flux (the dynamic process of autophagic degradation
activity) produces anti-prion effects, new treatments based on its activation have been
tested to develop therapeutic strategies for prion diseases. In this review, we summarize
previous and recent findings concerning the role of autophagy in TSE.
Keywords: autophagy, LC3, p62, neurodegenerative diseases, prion diseases, Creutzfeldt-Jakob disease,
scrapie, therapies
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INTRODUCTION
Transmissible spongiform encephalopathies (TSE), or prion
diseases, are a group of fatal neurodegenerative disorders that
affect both humans and animals (Prusiner, 1982). Human prion
diseases include kuru, the various forms of Creutzfeldt-Jakob
disease (CJD), Gerstmann-Sträussler-Scheinker (GSS) syndrome,
fatal familial insomnia, sporadic fatal insomnia, and the variably
protease-sensitive prionopathy (Imran and Mahmood, 2011a). In
animals, they include, but are not limited to, bovine spongiform
encephalopathy (BSE) in cattle, classical and atypical scrapie in
sheep and goats, and chronic wasting disease in cervids (Imran
and Mahmood, 2011b). Ovine scrapie was the first TSE described
and constitutes one of the most widely studied models of these
pathologies (Pattison and Jones, 1967).
Prion diseases are characterized by a long asymptomatic
incubation period and a rapidly progressing pathology that leads
inevitably to death. According to the protein-only hypothesis
(Prusiner, 1982), TSE are caused by the conformational
conversion of native cellular prion protein (PrPc), which is
encoded by the prion protein (PRNP) gene, into an infectious
misfolded isoform named scrapie-associated prion protein
(PrPSc). Accumulation of PrPSc in the central nervous system
(CNS), which is believed to be the main pathogenic event
responsible for the pathological changes produced in TSE
patients, induces spongiform degeneration, glial activation
and neuronal loss (Wells and McGill, 1992; Wood et al.,
1997). Hence, prion diseases share profound similarities
with other neurodegenerative disorders associated with the
accumulation of misfolded protein aggregates like Alzheimer’s
disease, Parkinson’s disease and Huntington’s disease (Soto,
2003). Despite the similarities between these diseases, prions
remain unique since epidemiological data support their
ability to transmit under natural and experimental conditions
between individuals and, to a certain extent, between species
(Mays and Soto, 2016).
For years, TSE research field has focused on characterizing
the underlying molecular mechanisms of the basic pathological
processes involved in prion pathogenesis and neurodegeneration.
Unfortunately, despite the great efforts of the researchers, these
mechanisms are not completely understood. Recent evidence
has emerged implicating impaired protein homeostasis as a
major cause of toxicity common to prion diseases (Goold
et al., 2015). Cellular homeostasis requires a proper balance
between the protein degradation and synthesis to eliminate
and replace proteins, respectively. In this regard, cells employ
various biological mechanisms that control protein degradation,
which include lysosomal routes such as the autophagic pathway
(Majeski and Dice, 2004). Existing data suggest that neurons fail
to recover homeostasis after exposure to PrPSc, which ultimately
leads to neuronal dysfunction and death by mechanisms
that originate as a survival response to intracellular PrPSc
accumulation (Mays and Soto, 2016). Indeed, many studies have
identified autophagic dysregulation in TSE models (Boellaard
et al., 1989, 1991; Liberski et al., 2004; Sikorska et al., 2004;
Mok et al., 2007; Xu et al., 2012; Homma et al., 2014;
Moon et al., 2016c; Llorens et al., 2017; Thellung et al.,
2018; Lopez-Perez et al., 2019a,b, 2020), although the casual
relationship between these observations and disease pathogenesis
is currently unknown. Considering the impact of autophagy in
other neurodegenerative disorders (Bursch and Ellinger, 2005;
Rubinsztein, 2006), in this review we summarize, evaluate and
discuss previous and recent findings concerning the role of this
process, as well as the therapeutic effects of its modulation,
in prion diseases.
AUTOPHAGY
Autophagy is a fundamental pathway of cellular catabolism and
recycling, in which nonessential cytoplasm and unwanted or
damaged components are sequestered in vesicles and delivered to
lysosomes for degradation, thus maintaining homeostatic balance
(Rubinsztein, 2006). There are three different types of autophagy
in mammalian cells classified according to their method of
delivery to the lysosome: macroautophagy, microautophagy
and chaperone-mediated autophagy (CMA) (Mizushima et al.,
2008). As macroautophagy is the most prevalent and best
characterized form, it is often referred to as autophagy.
During macroautophagy (hereafter autophagy), portions of the
cytoplasm are surrounded by an isolation membrane of unknown
origin named phagophore. Elongation and fusion of the edges
of the phagophore engulf the cytoplasmic material inside a
double-membrane vesicle, with about 1 µm diameter, called
autophagic vacuole or autophagosome. Sequestered contents can
include individual, aggregated and misfolded proteins, whole
organelles such as parts of the endoplasmic reticulum (ER),
mitochondria and peroxisomes, and even invading pathogens.
The outer membrane of the autophagosome then docks
and fuses with the lysosome to form an autophagolysosome
or autolysosome, where the autophagic cargo, together with
the inner membrane, is degraded by lysosomal hydrolases.
Eventually, the resulting macromolecules are released back into
the cytosol and recycled by the cell (Yoshimori, 2004; Rubinsztein
et al., 2012; Feng et al., 2014).
MOLECULAR MECHANISMS
Autophagy is a highly conserved process from yeast to human
(Reggiori and Klionsky, 2002). To date, independent genetic
screens in yeast model systems, mainly in Saccharomyces
cerevisiae, have allowed the identification of about 30
autophagy-related (ATG) genes, many of which have
known homologs in higher eukaryotes (Bednarczyk et al.,
2018). Among these ATG genes, one subset is required for
autophagosome formation, whose corresponding encoded
proteins are known as the “core autophagy machinery” (Xie
and Klionsky, 2007). Autophagosome formation can be
summarized in several distinct stages: induction, nucleation,
expansion, fusion, and cargo degradation/recycling (Yin
et al., 2016). For simplicity, we will use in this section of
the review the unified yeast nomenclature when describing
autophagy-related proteins.
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Induction
Initiation of the autophagic process is carried out by the
Atg1 kinase complex, composed of the serine/threonine kinase
Atg1, its regulatory subunit Atg13, and the Atg17-Atg31-Atg29
scaffolding subcomplex (Figure 1A; Kamada et al., 2010). The
stimuli necessary to induce autophagy are detected by nutrient-
sensing pathways such as the target of rapamycin complex 1
(TORC1; mTORC1 in mammals), which is considered the main
negative regulator of autophagy (Laplante and Sabatini, 2012).
Under normal conditions, TORC1 maintains autophagy at a basal
level by phosphorylating certain proteins including Atg1 and
Atg13, which impedes activation of the Atg1 kinase complex.
During starvation, or treatments with chemical compounds such
as rapamycin, an intracellular signaling cascade inhibits TORC1,
resulting in the dephosphorylation of Atg1 and Atg13. In this
situation, Atg1 auto-phosphorylates, increases its kinase activity,
and recruits and activates other Atg proteins, allowing them to
be localized to the phagophore assembly site (PAS) and begin
nucleation (Ariosa and Klionsky, 2016).
Nucleation of the Phagophore
In autophagy, nucleation refers to the process of mobilizing
and recruitment of proteins needed for phagophore expansion
to the PAS (Yin et al., 2016). The autophagy-specific class
III phosphatidylinositol 3-kinase complex I (PtdIns3K-C1),
which is comprised of the lipid kinase Vps34, the regulatory
kinase Vps15, Vps30/Atg6 (BECN1 in mammals) and Atg14,
is the nucleation machinery that is recruited to the PAS upon
induction of autophagy (Figure 1B; Birgisdottir et al., 2019). The
function of this set of proteins is to catalyze the conversion of
phosphatidylinositol (PtdIns) to phosphatidylinositol 3-phospate
(PtdIns3P). This molecule then serves as a signal that recruits
other Atg proteins that recognize and preferentially bind
PtdIns3P at the nucleation site (Ariosa and Klionsky, 2016).
Another important negative regulator of autophagy is the Atg6-
Bcl-2 interaction complex. Under normal conditions, Bcl-2
directly inhibits autophagy by binding to Atg6, while during
starvation, Bcl-2 dissociates from Atg6, allowing Atg6 to associate
with the PtdIns3K-C1 complex and perform its function in
PtdIns3P formation (Ariosa and Klionsky, 2016).
Expansion and Maturation Into an
Autophagosome
Autophagy employs the use of two ubiquitin-like (Ubl)
conjugation systems to extend and elongate the phagophore.
These systems involve the Ubl proteins Atg12 and Atg8
[microtubule-associated protein 1 light chain 3 (MAP1LC3, or
LC3) in mammals] (Figure 1C; Ohsumi, 2001). During the first
Ubl conjugation reaction, Atg12 associates with Atg5, which
depends on the E1 activating and E2 conjugating enzymes
Atg7 and Atg10 (Mizushima et al., 2003b). The Atg12-Atg5
conjugate subsequently forms a multimeric complex with Atg16
(Mizushima et al., 2003a). In the second Ubl reaction, Atg8 is
first cleaved off by the protease Atg4, and then recognized and
processed by the E1 activating and E2 conjugating enzymes Atg7
and Atg3. The proteolyzed protein Atg8 (LC3-I in mammals)
is then covalently attached to phosphatidylethanolamine (PE) to
form Atg8-PE (LC3-II in mammals), a reaction that is facilitated
by the E3-like Atg12-Atg5-Atg16 complex (Feng et al., 2014;
Ariosa and Klionsky, 2016). Although these two conjugates are
essential for autophagy and localize at the PAS, how their covalent
modification reactions contribute to phagophore expansion and
maturation is unknown (Ariosa and Klionsky, 2016). To further
expand the phagophore, the membrane necessary is delivered
from peripheral sites to the PAS by the shuttling of the
transmembrane protein Atg9 (Mari et al., 2010).
Fusion, Degradation, and Recycling
Upon completion of the autophagosome, it targets to, docks
and then fuses with the degradative organelle (Yin et al., 2016).
The Atg12-Atg5-Atg16 complex is mainly localized on the outer
side of the autophagosome and is released into the cytosol
before or after autophagosome completion (Yang and Klionsky,
2009). In contrast, Atg8-PE is present both on inner and outer
autophagosome membranes (Kabeya et al., 2000). The Atg8-PE
that resides on the outer side is released by a second Atg4-
dependent cleavage, a deconjugation necessary to initiate the
fusion stage, whereas the inner population remains inside the
vesicle and is degraded in the degradative organelle (Yang and
Klionsky, 2009; Nair et al., 2012). This protein is currently
the most widely used marker to monitor autophagic activity
because the amount of the membrane-associated LC3-II form in
mammals reflects the number of autophagosomes (Mizushima
and Yoshimori, 2007). After fusion, the cargo is delivered inside
the degradative organelle and degraded by resident hydrolases.
Metabolites generated in the proteolytic process are released
back into the cytosol through various permeases located in the
membrane and reutilized by the cell (Ariosa and Klionsky, 2016).
PHYSIOLOGICAL ROLES OF
AUTOPHAGY
Autophagy is an essential survival mechanism that primarily
acts as an adaptive catabolic response to environmental
adversity. This process rapidly increases its activity when
cells are exposed to extreme conditions of metabolic stress,
especially during nutrient deprivation, but also in the absence
of growth factors, oxygen or energy (Levine and Kroemer,
2008; Kroemer et al., 2010). The basic response of autophagy
is to serve as a source of energy during starvation: when
there is a lack of nutrients or resources become limited,
the cell is forced to break down and recycle part of
its own reserves, including pre-existing material such as
proteins, lipids and carbohydrates, to meet demands for
metabolic substrates and stay alive until the situation improves
(Levine and Kroemer, 2008).
However, constitutive turnover of cytoplasmic material by
basal autophagy, even during favorable growth conditions, is
also essential for proper cell physiology (Yin et al., 2016). In
this regard, cells employ several quality control mechanisms
aimed at degrading and recycling intracellular proteins and
components to maintain normal internal homeostasis and
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FIGURE 1 | Molecular mechanisms of the core autophagy machinery and alterations (up/down) of autophagy-related genes and proteins involved in
autophagosome formation in prion disease models. Figure shows the molecular mechanisms of (A) induction, (B) nucleation of the phagophore, and (C) expansion
and maturation into an autophagosome. The unified yeast nomenclature has been used for simplicity. P, phosphate; PtdIns3K-C1, phosphatidylinositol 3-kinase
complex I; PtdIns, phosphatidylinositol; PtdIns3P, phosphatidylinositol 3-phospate; PE, phosphatidylethanolamine; sCJD, sporadic Creutzfeldt-Jakob disease; BSE,
bovine spongiform encephalopathy. Based on (Ariosa and Klionsky, 2016).
preserve viability, which include the ubiquitin-proteasome
system (UPS) and lysosomal routes such as the endocytic
and autophagic pathways (Majeski and Dice, 2004). The
UPS fundamentally breaks down short-lived proteins after
they have executed their function in the cell (Hochstrasser,
1995), while autophagy is responsible for the degradation
of long-lived proteins and whole organelles (Yoshimori,
2004). These proteolytic systems also confer a protective
effect against misfolded or damaged proteins. Under normal
conditions, cells efficiently control misfolded proteins by
enzyme- and chaperone-mediated folding. However, when
chaperone refolding fails, misfolded proteins are targeted
for degradation through combined proteolytic activity of
the UPS and autophagy, making interaction between these
systems essential for protein quality control (Zheng et al.,
2009). Existing data indicate that UPS inhibition by genetic
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or pharmacological manipulation induces autophagy as a
protective cell response (Pandey et al., 2007) and, conversely,
inhibition of autophagy increases proteasomal activity (Zhu
et al., 2007), suggesting that both systems act as compensatory
mechanisms in protein quality control. There are several
signaling proteins that connect the UPS with the autophagic
pathway, including p62 protein, or sequestosome 1 (SQSTM1),
a selective autophagy receptor that recognizes and shuttles
ubiquitinated proteins to the autophagosomes for degradation
(Bjorkoy et al., 2005, 2006). p62 can be degraded by autophagy,
since the levels of this protein decrease after treatment with
autophagy inducers such as rapamycin, but increase after
autophagy inhibition (Bjorkoy et al., 2005; Yue, 2007). Therefore,
p62 accumulation is considered a sign of autophagic malfunction
(Bjorkoy et al., 2009).
While cytosolic components and organelles are directed
to lysosomes for degradation via the autophagic pathway,
extracellular material and membrane proteins are directed
via the endocytic pathway, thus both autophagosomes and
endosomes converge in the lysosome to deliver their cargo.
However, in some situations, cells relieve intracellular
stress conditions by selective secretion of deleterious
or damaged material, such as proteins and RNA, to the
extracellular environment through exosomes (Baixauli et al.,
2014). These vesicles play a crucial role in intercellular
communication and, in coordination with autophagy, are
essential to maintain cell homeostasis, since modulation of
autophagy allows regulation of exosome biogenesis and release
(Fader and Colombo, 2006). Although autophagosomes
generally fuse with lysosomes, they can also fuse with
multivesicular bodies containing exosomes, forming a
vesicle called amphisome which subsequently fuses with
lysosomes (Hessvik and Llorente, 2018). Under induction of
autophagy, the multivesicular bodies target the autophagic
pathway, which restrains secretion of exosomes from the cell
(Fader et al., 2008).
Autophagy is also involved in other physiological processes,
such as cell remodeling during development, cell differentiation,
innate and adaptive immunity, genomic stability, longevity,
and cell death (Levine and Yuan, 2005; Lum et al., 2005;
Maiuri et al., 2007; Yorimitsu and Klionsky, 2007; Levine and
Kroemer, 2008; Mizushima et al., 2008). Through all these
functions, autophagy protects the organism against diverse
pathologies, and when it does not work correctly, promotes
the development of these. Defective autophagy has been linked
to a broad range of human and animal diseases, including
cardiomyopathies, infections, cancer, and protein misfolding
disorders that lead to neuronal, muscle and liver degeneration
(Levine and Kroemer, 2008).
AUTOPHAGY IN NEURODEGENERATIVE
DISEASES
Although autophagy physiologically occurs at basal level in
cells, the demand for basal autophagy is tissue-specific. Those
tissues whose cells do not divide after differentiation, such as
neurons, myocytes or hepatocytes, are highly dependent on
basal autophagy degradation, since they are predisposed to
accumulation of misfolded proteins and damaged organelles that
could be diluted through cell division (Komatsu et al., 2005,
2007; Hara et al., 2006; Komatsu et al., 2006; Nakai et al.,
2007). In neurons, the efficient transport of proteins, organelles
and autophagosomes at significant distances from the cell body
through axons and dendrites (collectively known as neurites)
could be altered by a defective autophagic mechanism, which
would affect intercellular communication and, subsequently,
contribute to neurite degeneration and neuronal cell death (Chu
et al., 2009; Son et al., 2012). Additionally, neuronal autophagy
has been implicated in regulation of neurite length, synapse
growth and plasticity required for learning and memory (Son
et al., 2012). Compared to other systems, the CNS displays low
levels of autophagosomes under basal conditions and even during
starvation, probably because neurons remove autophagosomes
faster, or because they do not require a substantial level
of autophagy due to their susceptibility to autophagic flux
imbalance (Ariosa and Klionsky, 2016). The described evidence
shows that basal autophagy plays a critical role in maintaining
neuronal health and function, and is controlled more tightly
in these cells than that of non-neuronal cells, since the intense
sensitivity of the CNS to accumulation of protein aggregates
and damaged organelles could easily lead to the development
of neurodegenerative diseases, even in absence of expression of
disease-associated mutant proteins (Frake et al., 2015; Kiriyama
and Nochi, 2015).
A common feature of various neurodegenerative diseases is
the intracellular accumulation of aggregates of toxic proteins that
by some means escape the degradation process, which inevitable
leads to dysfunction and neuronal death (Nixon, 2005; Shibata
et al., 2006). The mere existence of these aggregates is a sign of
malfunction of neuronal degradative mechanisms (Chu, 2011).
Although most of these diseases are age-related, several in vivo
studies have provided a direct correlation between defective
autophagy and neurodegeneration. Neural-tissue deletion of Atg
genes in mice results in accumulation of ubiquitin-positive
protein aggregates in neurons, neurodegeneration, neuronal loss,
progressive motor deficits and abnormal reflexes, which resemble
the clinical and pathological characteristics of neurodegenerative
diseases (Hara et al., 2006; Komatsu et al., 2006). Indeed,
abnormal autophagic activity has frequently been observed
in specific neuronal populations in Alzheimer’s disease (AD),
Parkinson’s disease (PD), Huntington’s disease (HD), and prion
diseases (Boellaard et al., 1989, 1991; Ravikumar et al., 2002;
Qin et al., 2003; Webb et al., 2003; Liberski et al., 2004;
Sikorska et al., 2004; Iwata et al., 2005; Nixon et al., 2005;
Rubinsztein et al., 2005; Berger et al., 2006; Mizushima and Hara,
2006; Ventruti and Cuervo, 2007).
Autophagic vacuoles are abundant in AD brains, mainly
within dystrophic neurites, but also in the cell body of
affected neurons (Nixon et al., 2005). Intracellular amyloid-
β (Aβ) increases autophagic activity and, in turn, autophagic
vacuoles may contribute to generate the pathogenic peptide,
since they are a major reservoir of intracellular Aβ and
the crucial elements for its formation (Yu et al., 2005;
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Ling et al., 2009; Pajak et al., 2009a,b; Lipinski et al., 2010). In
AD, retrograde transport of autophagosomes along microtubules
and their maturation into autophagolysosomes are impaired,
leading to ineffective degradation and excessive accumulation of
immature autophagic vacuoles in degenerate neurites (Nixon,
2007; Boland et al., 2008). Increase or hyperphosphorylation
of tau protein, which controls the stability of microtubules,
may affect the activity of these tubular structures, disrupting
neuronal functions of autophagic transport through neurites and
synapses (Funderburk et al., 2010). In addition, the expression
of ATG5, ATG12, LC3, and BECN1 decrease in AD brains as
the disease progresses (Pickford et al., 2008; Ma et al., 2010).
This combination of autophagy induction, defective maturation
and clearance of Aβ-generating autophagosomes, and progressive
reduction of key autophagy proteins, suggests an impairment of
autophagic activity, which probably impedes the degradation of
Aβ and creates the appropriate circumstances for its aggregation
and accumulation in AD (Nixon, 2007; Boland et al., 2008;
Jaeger et al., 2010).
Similarly, PD patients display characteristics of autophagy in
degenerating neurons of the substantia nigra (Anglade et al.,
1997). Inhibition of both CMA and macroautophagy leads
to accumulation of α-synuclein (Webb et al., 2003; Cuervo
et al., 2004; Vogiatzi et al., 2008), while autophagic activation
through BECN1 stimulation reduces α-synuclein levels in the
limbic system and improves synaptic and dendritic pathology
(Spencer et al., 2009). In addition, overexpression of several
familial PD-associated molecules, such as the wild-type form
and the mutant forms of α-synuclein, disrupts the autophagic
machinery, suggesting that autophagy may play a relevant role
in the pathogenesis of PD (Cuervo et al., 2004; Xilouri et al.,
2009; Winslow et al., 2010). Endosomal membranes and vacuoles
with ultrastructural characteristics of autophagosomes are also
increased in several experimental models of HD (Kegel et al.,
2000). While wild-type huntingtin (HTT) regulates autophagy in
response to ER stress, expression of its mutant form disrupts ER
function and increases autophagic vacuoles (Atwal and Truant,
2008). In HD, autophagosomes form at normal rates and are
adequately eliminated by lysosomes, but they fail to efficiently
recognize and trap cytosolic cargo in their lumen, leading to
mutant HTT accumulation in cells (Martinez-Vicente et al.,
2010). Moreover, recruitment of BECN1 by accumulated mutant
HTT and mutations that affect the dynein motor machinery also
reduce autophagic clearance of the toxic protein (Ravikumar
et al., 2005; Shibata et al., 2006).
All these observations have generated controversy regarding
whether the increase of autophagosomes in degenerating neurons
plays a protective homeostatic role, or instead contributes to
pathogenic neuronal death (Son et al., 2012). Early studies
showing accumulation of autophagosomes in brains affected with
neurodegenerative diseases initially suggested that autophagy
may contribute to the pathogenesis of these disorders (Levine
and Kroemer, 2008). However, there is wide evidence that
both Aβ peptide and the mutant forms of α-synuclein and
HTT are substrates for autophagic degradation (Ravikumar
et al., 2002; Webb et al., 2003; Shin et al., 2014). Induction
of autophagy by pharmacological or genetic manipulation
has beneficial effects and reduces the toxic protein levels in
several models of neurodegenerative diseases, while its inhibition
produces an opposite response (Rubinsztein et al., 2007).
Therefore, the prevailing explanation is that autophagy protects
against neurodegenerative diseases and the accumulation of
autophagosomes produced by the expression of mutant proteins
primarily represents an attempt to eliminate those proteins from
the cell (Levine and Kroemer, 2008). The development of the
disease implies that autophagy may reach a saturation point
in which its capacity to degrade aggregated mutant proteins is
exceeded, or that there are defects in the autophagic pathway
produced by the same pathological factors that trigger the
disease (Levine and Kroemer, 2008). In either case, impairment
of autophagy likely contributes to accumulation of damaged
organelles and toxic proteins, leading to the neurodegenerative
conditions observed in these diseases (Son et al., 2012).
AUTOPHAGY IN PRION DISEASES
Until three decades ago, data on autophagy in TSE were very
limited and consisted mostly of ultrastructural studies of electron
microscopy. Autophagic vacuoles in prion diseases were first
described by Boellard et al. in experimental models of CJD
and scrapie in mice and hamsters (Boellaard et al., 1989,
1991). Thereafter, the presence of multivesicular bodies and
autophagic vacuoles was also observed in prion-infected neuronal
cell cultures that displayed characteristics of neurodegeneration
(Schatzl et al., 1997). Numerous large multivesicular bodies,
autophagolysosomes and autophagosomes at different stages of
formation have subsequently been described in neuronal cell
bodies, dystrophic neurites and synapsis in brain biopsies from
patients with various forms of human prion disease and in
experimentally induced scrapie, CJD and GSS (Liberski et al.,
2004, 2011; Sikorska et al., 2004). These findings suggest a
crucial role for autophagy in TSE, which encouraged many
researchers to analyze in detail this process in prion infection-
related conditions. However, up to date, the role of autophagy in
prion diseases is still controversial. Authors have used different
approaches to quantify or monitor autophagy. Results are
different in vitro and in vivo and, even in the same species,
regulation can be dissimilar in different anatomical areas of the
CNS. We will try to identify and discuss hereafter the origin of
these discrepancies to get a global vision of autophagy studies
in prion diseases.
Is the Cellular Prion Protein Involved in
Autophagy Regulation?
Although a functional role for PrPc in modulating the
autophagic pathway has been suggested (Shin et al., 2013), PrPc
deficiency does not affect basal autophagy flux of Prnp-knockout
mice hippocampal neurons under normal culture conditions.
However, under stress conditions such as serum deprivation,
these cells show higher levels of LC3-II than neurons of wild-
type mice (Oh et al., 2008). It was subsequently reported that
autophagy regulation by PrPc might be related to its known
protective role against oxidative stress as the deficiency of PrPc
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impair autophagy flux via hydrogen peroxide (H2O2)-induced
oxidative stress (Oh et al., 2012), and that PrPc expression
increases autophagic activity through modulation of alpha7
nicotinic acetylcholine receptor (α7nAchR) to protect neurons
against PrP106-126 toxicity (Jeong and Park, 2015). Thus, PrPc
seems to regulate autophagy only under stress conditions. Similar
properties have been attributed to HTT regulating autophagy in
response to ER stress (Atwal and Truant, 2008).
Dysregulation of Autophagy in Prion
Diseases
Expression studies of genes and proteins involved in the
autophagic pathway have been performed in order to decipher
the implication of autophagy in the neuropathology associated to
TSE. Thus, the expression levels of several of these molecules are
altered in several prion disease models both in vivo and in vitro
(Figure 1 and Table 1). However, reported changes and their
interpretation are different, and even contradictory, depending
on the experimental model used.
Downregulation of mRNA transcripts of positive gene
regulators of autophagy such as BECN1, ATG5, ATG9, FBXW7
(F-box and WD repeat domain containing 7) and GAS5 (growth
arrest-specific 5) has been observed in the CNS of scrapie-
infected wild-type or transgenic mice and sheep naturally
affected with classical scrapie (Mok et al., 2007; Lopez-Perez
et al., 2019b, 2020). These changes were associated with an
impairment of autophagy at late stages of the disease, as only
animals displaying clinical signs showed altered expression
profiles. On the contrary, the encoded protein of FBXW7
is upregulated at the early stage of infection in the scrapie
murine brain cell line SMB-S15 and in brains of scrapie-agent
263K-infected hamsters, leading to degradation of mTORC1
and increase of autophagic flux (Xu et al., 2016). In these
cells, knockdown of ATG5 and FBXW7 inhibited autophagic
flux and increased PrPSc accumulation. Both in vivo and
in vitro models suggest that downregulation of autophagy
regulator genes could inhibit the process and favor/stimulate
prion accumulation.
However, studies analyzing other molecular pathways related
to autophagy report an increase of autophagy activity at late
stages of the disease. For example, mitochondrial dysfunction is
a common and prominent feature of prion diseases (Zhu et al.,
2018). Mitophagy, which is the specific autophagic elimination
of defective mitochondria, is activated in prion-infected SMB-
S15 cells and in mice infected with scrapie strains 139A and
ME7 at the terminal stage of the disease, represented by the
transcriptional and protein increase of the two essential elements
regulating mitophagy activity: PINK1 (PTEN-induced kinase 1)
and Parkin (Gao et al., 2020). Transcripts of SCRG1 (scrapie-
responsive gene 1), whose encoded protein has been linked to the
presence of autophagic vacuoles in neurons of scrapie-infected
mice at terminal stage, are also enhanced in sporadic CJD (sCJD)
and murine models of scrapie and BSE (Dandoy-Dron et al.,
1998, 2000; Dron et al., 1998, 2005, 2006). Similarly, autophagy
activator genes HSPA8 [heat shock protein family A (Hsp70)
member 8] and HSPB8 [heat shock protein family B (small)
member 8] are upregulated in the CNS of sCJD-infected Tg340-
PRNP129MM mice at clinical stage, sCJD patients (Llorens et al.,
2017), and naturally scrapie-infected sheep (Serrano et al., 2011).
Upregulation of these genes involved in autophagy regulation
may reflect an attempt of the cell to induce autophagy, although
over time, this process may become impaired, resulting in
the accumulation of autophagic vacuoles as observed in other
neurodegenerative diseases (Polajnar and Zerovnik, 2014).
Nevertheless, drawing conclusions from expression changes
of genes involved in the complex autophagy machinery is
complicated. Universal autophagy markers could help in this
analysis. The study of p62 protein, in combination with other
assays such as the monitoring of LC3-II conversion, is widely
used to evaluate autophagic activity (Klionsky et al., 2016; Zhang
et al., 2016). Downregulation of the amount of both LC3-II and
p62 in human and mouse neuronal cells infected with human
prions was related to an activation of the autophagic flux in
response to prion infection (Moon et al., 2016c). Interestingly,
overexpression of LC3-II and p62 in prion-infected cell cultures
and in brains of 263K-infected hamsters and 22L-infected mice
was also associated with an activation of autophagy to promote
PrPSc degradation (Homma et al., 2014). Similarly, the increment
of these proteins was also observed in neuronal cells treated
with amino-terminally truncated prion protein (PrP90-231),
which suggested that PrP stimulates autophagic flux but leads
progressively to the accumulation of autophagolysosomes with
impaired resolution ability (Thellung et al., 2018). The opposite
results about LC3/p62 regulation could be the consequence of
analyzing different points of autophagy kinetics, or maybe TSE
models are reacting differently to different prion strains. In
addition, most of these studies were performed using neuronal
cells and very few have focused on analyzing autophagic changes
in glial cells. In fact, astrocyte reactivity resulting from activation
of the unfolded protein response has been shown to be crucial
in mediating prion neuropathology (Smith et al., 2020). We
observed p62 immunolabeling in both neuronal and glial cells in
scrapie-infected sheep and mice (Lopez-Perez et al., 2019b, 2020),
but more studies including these cell populations are needed in
order to deciphering the biological relevance of these findings.
Murine models allow the investigation of preclinical stages
of the disease. Using mice overexpressing the highly sensitive
VRQ/VRQ variant of the ovine PRNP gene, we described a
downregulation of LC3 and upregulation of p62 in highly
prion-affected brain areas of scrapie-infected Tg338 mice at
clinical stage (Lopez-Perez et al., 2020). The absence of
changes in scrapie-infected mice at preclinical stage indicates
that impairment of autophagy takes place at the last stage
of prion infection and is not the result of depletion or
exhaustion of the autophagic machinery. In accordance to
this hypothesis, the expression of autophagy related genes
was neither altered at early stages of the disease. However,
these results differ from those observed in other murine
models. Conversion of LC3-I into LC3-II and downregulation
of p62 have been reported in the terminal stage of scrapie
263K-infected hamsters (Xu et al., 2012). Changes reported
in hamsters were similar to those observed in patients
with genetic prion diseases (Xu et al., 2012). As PrPc
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TABLE 1 | Alterations (up/down) of autophagy-related genes and proteins not involved in autophagosome formation in prion disease models.
Molecule Regulation Prion disease model References
p62 Up In vitro: (protein) prion-infected cell cultures and neuronal cells
infected with amino-terminally truncated prion protein (PrP90-231)
Homma et al., 2014;
Thellung et al., 2018
In vivo: (protein) brains of naturally classical scrapie-infected sheep,
experimentally atypical scrapie-infected sheep, scrapie-infected
Tg338 mice at clinical stage, scrapie 22L-infected mice and scrapie
263K-infected hamsters
Homma et al., 2014;
Lopez-Perez et al.,
2019a,b, 2020
Down In vitro: (protein) prion-infected human and mouse neuronal cells Moon et al., 2016c
In vivo: (protein) brains of scrapie 263K-infected hamsters at
terminal stage and human genetic prion diseases
Xu et al., 2012
FBXW7 Up In vitro: (protein) prion-infected SMB-S15 cells at early stage Xu et al., 2016
In vivo: (protein) brains of scrapie 263K-infected hamsters Xu et al., 2016
Down In vivo: (gene) brains of scrapie-infected Tg338 mice at clinical stage Lopez-Perez et al., 2020
GAS5 Down In vivo: (gene) brains of scrapie-infected Tg338 mice at clinical stage Lopez-Perez et al., 2020
SCRG1 Up In vivo: (gene) brains of scrapie- and BSE-infected mice and sCJD
patients; (protein) brains of scrapie-infected mice at terminal stage
Dandoy-Dron et al., 1998,
2000; Dron et al., 1998,
2005, 2006
HSPA8, HSPB8 Up In vivo: (gene) brains of sCJD-infected Tg340 mice at clinical stage,
sCJD patients and naturally classical scrapie-infected sheep
Serrano et al., 2011;
Llorens et al., 2017
PINK1, Parkin Up In vitro: (gene and protein) prion-infected SMB-S15 cells Gao et al., 2020
In vivo: (protein) brains of scrapie 139A- and ME7-infected mice at
terminal stage
BSE, bovine spongiform encephalopathy; sCJD, sporadic Creutzfeldt-Jakob disease.
seems to have a role in autophagy regulation under stress
conditions, overexpression of PrPc in transgenic mice could
alter the response.
Models can react differently to prion infection, but could
autophagy also be regulated differently depending on the
prion strain? Analyzing the CNS of sheep naturally infected
with classical scrapie at clinical stage, we observed changes
compatible with induction of autophagy in brain regions with
low levels of prion-related lesions, such as basal ganglia and
cerebellar Purkinje cells, which displayed an upregulation of
both p62 and LC3 proteins (Lopez-Perez et al., 2019b). In
these animals, p62 was overexpressed in most of the CNS
areas. However, in brains from sheep experimentally infected
with atypical scrapie at clinical stage, LC3 levels did not
change and p62 was only increased in the areas most affected
by prion toxicity (Lopez-Perez et al., 2019a). In addition,
p62 positively correlated both with histopathological lesions
and PrPSc deposits in the latter model. Considering the
accumulation of p62 as a marker for autophagy malfunction,
these results indicate that impairment of autophagy is limited
to brain areas displaying high levels of prion-related lesions
in atypical scrapie, unlike the classical form of the disease
where this impairment seems to occur along the brain. The
differences observed between the two forms of scrapie could
reflect differences in the toxicity of both prions, as atypical
scrapie displays longer incubation periods than the classical
form. In line with these findings, a recent study reported
that strain-dependent incubation period is negatively correlated
with PrPSc deposition and neuroinflammation, but positively
with autophagy (Mammadova et al., 2020). Retinas from
cattle inoculated with classical BSE displayed an upregulation
of autophagy indicated by the increase of LC3-II, whereas
those inoculated with atypical BSE displayed a downregulation,
which suggests that autophagic dysfunction contributes to
increased PrPSc accumulation in atypical BSE, leading to
greater neuroinflammation, shorter incubation periods and,
therefore, an accelerated disease progression when compared
to classical BSE.
Autophagic impairment has also been suggested in sCJD
cases, where LC3-II and DJ-1 (protein deglycase DJ-1)
proteins are overexpressed, while ATG5 is downregulated
and LAMP2 (lysosome-associated membrane protein 2) is
unaltered (Llorens et al., 2017). These alterations, along
with the accumulation of autophagic vacuoles, abnormal
lysosomes and autophagolysosomes observed in neurons of
sCJD patients, suggest that, although autophagy mechanisms
may be activated in sCJD, this process is not fully functional.
Therefore, autophagic impairment does occur in prion diseases.
Despite the discrepancies observed between the different TSE
models, most of the reported results suggest a dysfunction of
autophagy at the last stage of the disease, although it is still
unknown whether such dysregulation is cause or consequence
of prion toxicity.
Autophagy in Prion Neuropathology
Despite the numerous studies reporting an abnormal autophagic
activity, the biological role of this process in prion diseases, as in
most neurodegenerative diseases, is currently unclear. Initially,
it was suggested its participation in prion neuropathology by
contributing to formation of spongiform changes (Liberski
et al., 2002, 2004, 2008, 2011). Although the histogenesis
of typical TSE vacuoles has yet to be explained, it has
been proposed that vacuolization is by some means related
to tissue destruction by autophagy, thus these vacuoles may
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originate abruptly from autophagic vacuoles with no detectable
transition stages (Liberski et al., 2008, 2011). Excessive PrPSc
accumulation could lead to overload of the catabolic machinery,
phagocytosis of neuronal cytoplasm and, finally, massive
elimination of damaged neurons by autophagy (Jeffrey et al.,
1992). The pathogenesis of dystrophic neurites, another constant
neurodegenerative alteration in TSE, is also unclear. It has
been suggested that autophagic vacuoles originate in the
neuronal cell body, flow down with axonal transport along
the neurites, and then, in the presence of an impairment of
that transport, are accumulated forming dystrophic neurites
(Liberski et al., 2011; Liberski, 2019), a reasoning which
resembles that described in AD (Nixon, 2007; Boland et al.,
2008).
Autophagy could also be a positive factor for prion
propagation. A moderate basal level of autophagy may promote
prion spreading during certain stages of infection by generating
smaller PrPSc seeds (Heiseke et al., 2010), which are more
efficient templates for the conversion of PrPc into PrPSc
than larger aggregates (Silveira et al., 2005). In addition,
proteasome impairment in prion-infected neuronal cells results
in formation of large cytosolic perinuclear aggresomes containing
PrPSc (Kristiansen et al., 2005). Similar structures were found
in brains of prion-infected mice. PrPSc aggresomes may
generate prion seeds (Cohen and Taraboulos, 2003), trigger
autophagy (Kopito, 2000; Garcia-Mata et al., 2002) and,
in turn, be sequestered by autophagosomes that fuse with
lysosomes containing PrPSc, where the nucleation process
of forming more PrPSc can be initiated or perpetuated
(Liberski et al., 2008).
In contrast to this disease-promoting role, it is also likely that
the increment of autophagic vacuoles observed in prion disease
models is due to the activation of the autophagic machinery
as a defense mechanism that reflects the effort of neurons
to survive in the harmful environment produced by PrPSc
accumulation, leading even to degradation of prions (Heiseke
et al., 2010). PrPc is a plasma membrane-anchored glycoprotein
that cycles between the cell surface and intracellularly via
endosomal vesicles (Vey et al., 1996; Peters et al., 2003).
After internalization, PrPc traffics to early endosomes where
it is directed to recycling endosomes to be returned to the
plasma membrane or to multivesicular bodies to be degraded
by lysosomes (Campana et al., 2005). PrPSc also appears to
traffic along the same endo-lysosomal pathway (Yim et al., 2015).
There are two main PrPSc populations within the infected cell:
a population on the cell surface consisting of newly formed
PrPSc, which is highly labile, metabolizes rapidly and is a
substrate for non-autophagic lysosomal degradation (Caughey
and Raymond, 1991; Goold et al., 2013), and an internalized
population comprising most of total cellular PrPSc, which is
more aggregated, is relatively stable and is subject to autophagic
and proteasomal degradation (Boellaard et al., 1991; Caughey
and Raymond, 1991; Heiseke et al., 2010; Goold et al., 2013;
Yao et al., 2013). While implicated in the clearance of disease-
associated proteins, including PrPSc, degradation by the UPS may
be restricted to soluble misfolded proteins or smaller oligomeric
forms (Li et al., 2010; Goold et al., 2013, 2015; Bhat et al., 2014).
For larger, more insoluble aggregates, the catalytic chamber of the
proteasome may remain inaccessible, preventing their effective
degradation (Qin et al., 2003; Scotter et al., 2014). In fact, PrPSc
does not seem to be ubiquitinated to a significant degree and its
status as a proteasome substrate remains controversial (Goold
et al., 2015). Several studies have shown that prion infection
inhibits UPS activity, likely by direct interaction between PrPSc
and the 20 S proteasome core particle (Kristiansen et al., 2007;
Deriziotis et al., 2011; McKinnon et al., 2016). In the context
of UPS impairment, an upregulation of autophagy has been
described, which may facilitate the clearance of larger aggregates
(Korolchuk et al., 2010; Goold et al., 2015). Indeed, PrPSc
colocalizes with lysosomal markers in vivo (Dearmond and
Bajsarowicz, 2010) and, despite PrPSc deposits do not colocalize
with autophagosomes in brains of scrapie infected hamsters, they
do colocalize in prion-infected SMB-S15 cells after treatment
with bafilomycin A1 (Xu et al., 2012). In addition, although
the more usual places of PrPSc accumulation are the plasma
membrane and the endosomal vesicles (Mays and Soto, 2016),
and the majority of intracellular PrPSc is found within the endo-
lysosomal system (Goold et al., 2015), some PrP misfolded forms
harboring similarities with infectious PrPSc also appear to be
present at the ER and cytosol (Mays and Soto, 2016). Since the
ER lumen lacks degradation machinery, misfolded proteins are
retro-translocated to the cytosol for degradation and, eventually,
irreversibly aggregated ER proteins are targeted for lysosomal
degradation via autophagic pathways (Goold et al., 2015). Hence,
it is assumed that autophagy may be used by the cell to
control or counteract prion infection providing a neuroprotective
effect, while lysosomal dysfunction in combination with reduced
autophagy may contribute to the development of the disease
(Mok et al., 2007; Yao et al., 2013).
Autophagy in the Treatment of Prion
Diseases
At present there are no effective therapeutic or prophylactic
treatments for prion diseases, nor any useful drugs are
available. Existing data indicate that neurons do not recover
cell homeostasis after exposure to PrPSc, which eventually
leads to cell damage and neuronal cell death (Mays and
Soto, 2016). Considering the complex pathogenesis of TSE,
with many factors contributing to toxicity (Aguzzi and Falsig,
2012), treatments aimed at the basic toxic cause, that is, PrPSc
accumulation, should be effective in improving all aspects
of toxicity (Goold et al., 2015). There is wide experimental
evidence that induction of autophagy by chemical compounds
has beneficial effects and results in decreased PrPSc both
in vitro and in vivo, indicating that the stimulation of this
degradative pathway is sufficient to overcome the apparent
stability of internal PrPSc levels, whereas inhibition of the
process by pharmacological blocking or gene silencing leads to
prion accumulation (Heiseke et al., 2010; Goold et al., 2015;
Abdelaziz et al., 2019).
Imatinib increases lysosomal clearance of PrPSc in cultured
prion-infected cells by activating the autophagic machinery
(Ertmer et al., 2004, 2007). Both lithium and trehalose also
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improve PrPSc clearance in prion-infected neuroblastoma
and neuronal cells, respectively, by inducing autophagy
(Aguib et al., 2009; Heiseke et al., 2009). Treatment with
lithium not only decreases PrPSc levels, but also those
of PrPc, which indirectly contributes to PrPSc reduction
by limiting the amount of substrate available for prion
conversion (Heiseke et al., 2010). Both rapamycin and
metformin, which are known to inhibit mTORC1 signaling,
also decrease the PrPSc load in prion-infected neuroblastoma
and neuronal cells, respectively, by enhancing autophagy,
suggesting that both mTORC1-dependent and independent
autophagy induction pathways are involved in prion
degradation (Heiseke et al., 2009; Ishibashi et al., 2015;
Abdelaziz et al., 2020). In addition, both PrPc and PrPSc
are actively released into the extracellular environment
in association with exosomes, contributing to the spread
of prion infectivity between cells (Fevrier et al., 2004).
Autophagy stimulation with rapamycin strongly inhibits
exosomal prion release and hence the intercellular prion
dissemination, while its inhibition promotes the release of
exosomes and exosome-associated prions (Abdulrahman
et al., 2018). Natural compounds such as hinokitiol and
Ginsenoside-RG3, and other chemical compounds such as
AR-12, spermine, resveratrol, FK506 and astemizole, also have
anti-prion effects in vitro by induction of autophagy (Jeong
et al., 2012; Karapetyan et al., 2013; Nakagaki et al., 2013; Moon
et al., 2016a,b; Wang et al., 2016; Abdulrahman et al., 2017;
Phadwal et al., 2018).
Some of these treatments are effective also in vivo both
in terms of PrPSc reduction and beneficial clinical effects.
Intraperitoneal or oral application of trehalose, rapamycin,
imatinib, astemizole, AR-12 or FK506 to prion-infected mice
during the early stage of infection produces anti-prion effects,
such as extension of incubation period and survival time, and
delay of PrPSc neuroinvasion and the onset of clinical signs,
by induction of autophagosome formation and autophagy (Yun
et al., 2007; Aguib et al., 2009; Heiseke et al., 2009; Cortes
et al., 2012; Karapetyan et al., 2013; Nakagaki et al., 2013;
Abdelaziz et al., 2019). However, the administration of some
of these drugs when neuroinvasion has already accomplished
does not cause an evident clearance of PrPSc in the CNS,
probably because they do not efficiently cross the blood-brain
barrier or because their effective pharmacological concentrations
in vivo need to be higher (Yun et al., 2007; Heiseke et al., 2010;
Goold et al., 2015).
The molecular mechanisms that explain how autophagy
protects against neurodegeneration have not yet been
determined, although there are several hypotheses. In
addition to reducing the basic toxic protein that causes the
disease, autophagy has been proposed to eliminate damaged
organelles, such as the mitochondria, and attenuate the
apoptotic response to various forms of stress (Ravikumar et al.,
2006; Zhu et al., 2007). In general, it is reasonable to assume
that reducing PrPSc accumulation by stimulating autophagy
could represent an effective therapeutic strategy for prion
diseases in the near future, but additional and more complex
studies are necessary.
CONCLUSION
Although it is unknown whether the accumulation of autophagic
vacuoles in the CNS of several neurodegenerative diseases reflects
a proper response to deposition of misfolded proteins or an
impaired autophagosome clearance, there is direct evidence
indicating a decrease of autophagic activity or a deterioration of
the lysosomal degradation process. Dysregulation of autophagy-
related genes and proteins in various TSE models, along
with the abnormal accumulation of autophagic vacuoles, fully
supports the impairment of autophagy in prion diseases,
which will probably impede the clearance of protein aggregates
and damaged organelles from neurons and will contribute
to prion replication, neurodegeneration, and the development
of the disease. Altogether, research performed in this subject
indicates that autophagy is involved in prion neuropathology
in vivo and may be a potential target for therapeutic
intervention. Unfortunately, the analysis of autophagy in TSE
is currently incomplete. At the level of the whole organism,
the therapeutic effectiveness of manipulating autophagy may
depend on particular complex factors of the disease. More
research involving appropriate experimental in vivo models, late
preclinical animals, and different prion strains, will be necessary
to earn more detailed information on the molecular mechanisms
underlying autophagic impairment in prion diseases. Other
challenges include clarifying whether dysregulated autophagy
is a prerequisite or consequence of prion-induced toxicity,
or whether increased autophagy may have deleterious effects.
It is important to keep in mind that a certain level of
autophagy may be a positive modifier of prion infection
and susceptibility, so it cannot be ruled out that autophagy
plays a dual role combining pro- and anti-prion effects.
A better understanding of the role of autophagy in the
specific conditions of prion infection and its consequences for
neurodegeneration will benefit the development of innovative
and effective therapeutic strategies based on the manipulation
of this process.
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